XM无法为美国居民提供服务。
B
B

Biomarin

技术摘要

指标价值趋势
指标价值趋势
指标价值趋势
指标S3S2S1PR1R2R3

市场新闻

US FDA approves Pfizer's drug for rare bleeding disorder

UPDATE 2-US FDA approves Pfizer's drug for rare bleeding disorder Adds analyst estimates in paragraph 6, trial details in paragraph 8, and other treatments in paragraph 5, 10 and 11 By Sruthi Narasimha Chari and Christy Santhosh Oct 11 (Reuters) - The U.S. Food and Drug Administration approved Pfizer's PFE.N once-a-week injection for the two main types of a rare bleeding disorder called hemophilia, the company said on Friday.
B
P
S

US FDA approves Pfizer's drug for rare bleeding disorder

US FDA approves Pfizer's drug for rare bleeding disorder Oct 11 (Reuters) - The U.S. Food and Drug Administration approved Pfizer's PFE.N once-a-week injection for the two main types of a rare bleeding disorder called hemophilia, the company said on Friday. Reporting by Sruthi Narasimha Chari and Christy Santhosh in Bengaluru; Editing by Vijay Kish
B
P
S

U.S. Constellation Brands, Ge Vernova, Republic Services

U.S. RESEARCH ROUNDUP-Constellation Brands, Ge Vernova, Republic Services Oct 4 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Constellation Brands, Ge Vernova and Republic Services, on Friday. HIGHLIGHTS * Constellation Brands Inc STZ.N : JP Morgan cuts target price to $293 from $307 * Diamondback Energy Inc FANG.O : Gerdes Energy Research cuts to neutral from buy * Ge Vernova GEV.N : HSBC cuts to hold from buy * R
B
P
G
L
R

Biomarin Pharmaceutical Inc Reaffirming Its Long-Term Financial Guidance And Outlook That It Presented During Investor Day

BRIEF-Biomarin Pharmaceutical Inc Reaffirming Its Long-Term Financial Guidance And Outlook That It Presented During Investor Day Sept 24 (Reuters) - Biomarin Pharmaceutical Inc BMRN.O : BIOMARIN PHARMACEUTICAL INC: REAFFIRMING ITS LONG-TERM FINANCIAL GUIDANCE AND OUTLOOK THAT IT PRESENTED DURING INVESTOR DAY Source text for Eikon: [ID:n0001193125-2
B

Ascendis Pharma slips after $300 mln share offering launch

BUZZ-Ascendis Pharma slips after $300 mln share offering launch ** U.S.-listed shares of Ascendis Pharma ASND.O down 4.3% at $142.50 in extended trading as co seeks equity raise ** Denmark-based biopharma announces $300 mln offering of American depositary shares (ADSs) ** JP Morgan, Morgan Stanley, Evercore and Goldman Sachs are jt bookrunners ** On Mon, ASND shares closed up ~17% at $139.57 after co said its achondroplasia therapy TransCon CNP met main goal in trial to treat dwarfism ** Shares
B
G
J

商品详情

热门商品

免责声明: XM Group仅提供在线交易平台的执行服务和访问权限,并允许个人查看和/或使用网站或网站所提供的内容,但无意进行任何更改或扩展,也不会更改或扩展其服务和访问权限。所有访问和使用权限,将受下列条款与条例约束:(i) 条款与条例;(ii) 风险提示;以及(iii) 完整免责声明。请注意,网站所提供的所有讯息,仅限一般资讯用途。此外,XM所有在线交易平台的内容并不构成,也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。

所有在线交易平台所发布的资料,仅适用于教育/资讯类用途,不包含也不应被视为用于金融、投资税或交易相关咨询和建议,或是交易价格纪录,或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。

本网站上由XM和第三方供应商所提供的所有内容,包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接,皆保持不变,并作为一般市场评论所提供,而非投资性建议。所有在线交易平台所发布的资料,仅适用于教育/资讯类用途,不包含也不应被视为适用于金融、投资税或交易相关咨询和建议,或是交易价格纪录,或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解,XM非独立投资研究提示和风险提示相关资讯,更多详情请点击 这里

风险提示: 您的资金存在风险。杠杆商品并不适合所有客户。请详细阅读我们的风险声明